Cite
HARVARD Citation
Bannerji, R. et al. (2022). Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet. 9 (5), pp. e327-e339. [Online].